Table 3.
Multivariate Analyses of Prognostic Factors
| Prognostic Factor | Survival | |||||
|---|---|---|---|---|---|---|
| PFS | OS | |||||
| Hazard Ratio* | 95% CI | P | Hazard Ratio* | 95% CI | P | |
| Model including treatment as a variable (n = 80)† | ||||||
| Received rituximab-based therapy† | 0.23 | 0.10 to 0.55 | .0009 | 0.21 | 0.08 to 0.53 | .0009 | 
| CNS involvement | 5.66 | 1.61 to 19.97 | .007 | 3.88 | 1.09 to 13.86 | .04 | 
| > 1 extranodal site | 2.59 | 1.07 to 6.28 | .04 | 2.14 | 0.87 to 5.31 | .10 | 
| Hypoalbuminemia | 2.67 | 0.86 to 8.26 | .09 | 3.93 | 1.10 to 14.07 | .04 | 
| Model P | < .0001 | < .0001 | ||||
| Model excluding treatment as a variable (n = 80) | ||||||
| CNS involvement | 4.70 | 1.45 to 15.20 | .0099 | 3.61 | 1.06 to 12.32 | .04 | 
| Bone marrow involvement | 2.95 | 1.13 to 7.68 | .03 | 3.14 | 1.14 to 8.65 | .03 | 
| Hypoalbuminemia | 2.96 | 1.01 to 8.98 | .055 | 3.64 | 1.05 to 12.60 | .04 | 
| Model P | .0004 | .0003 | ||||
Abbreviations: PFS, progression-free survival; OS, overall survival.
Hazard ratios > 1 indicate a factor with poor prognosis, whereas those < 1 indicate a factor with favorable prognosis.
Treatment: rituximab-based therapy as a part of first-line post-transplantation lymphoproliferative disease therapy v not as part of first-line therapy.